Thermo Fisher Scientific Inc.
TMONYSEHealthcare● Active
$469.57
$-3.23(-0.68%)
Market Cap$174.5B
P/E Ratio—
52W High$643.99
52W Low$385.46
Thermo Fisher Scientific Inc. (TMO) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · TMO · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $44.56B | $42.88B | $42.86B | $44.91B | $39.21B |
| Cost of Revenue | $27.78B | $25.15B | $25.66B | $25.90B | $19.58B |
| Gross Profit | $16.78B | $17.73B | $17.19B | $19.01B | $19.63B |
| Gross Margin %(computed) | 37.66% | 41.34% | 40.12% | 42.33% | 50.07% |
| Operating Expenses | |||||
| R&D Expenses | $1.40B | $1.39B | $1.34B | $1.47B | $1.41B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $8.67B | $10.07B | $9.75B | $10.49B | $9.32B |
| Operating Income | $8.11B | $7.66B | $7.45B | $8.53B | $10.32B |
| Operating Margin %(computed) | 18.20% | 17.87% | 17.37% | 18.98% | 26.31% |
| Interest Income | $0.99B | $1.08B | $0.88B | $0.27B | $0.04B |
| Interest Expense | $1.42B | $1.65B | $1.49B | $0.73B | $0.54B |
| Income Before Tax | $7.27B | $7.00B | $6.24B | $7.66B | $8.84B |
| Income Tax Expense | $0.55B | $0.66B | $0.28B | $0.70B | $1.11B |
| Net Income | $6.74B | $6.33B | $6.00B | $6.95B | $7.72B |
| Net Margin %(computed) | 15.12% | 14.77% | 13.99% | 15.47% | 19.70% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $17.77 | $16.58 | $15.53 | $17.73 | $19.61 |
| Wtd Avg Shares | 0.38B | 0.38B | 0.39B | 0.39B | 0.39B |
| EBITDA | $11.47B | $11.80B | $11.20B | $11.94B | $11.97B |
| EBITDA Margin %(computed) | 25.73% | 27.52% | 26.12% | 26.59% | 30.52% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Thermo Fisher Scientific Inc. data
About Thermo Fisher Scientific Inc. (TMO) Income Statement
Thermo Fisher Scientific Inc. (TMO) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, TMO reported revenue of $44.56B, gross profit of $16.78B (gross margin 37.66%), and net income of $6.74B — a net profit margin of 15.12%.
Frequently asked questions
TMO · 4 questionsThermo Fisher Scientific Inc. (TMO) reported revenue of $44.56B for 2025, up 3.9% year-over-year.
TMO revenueTMO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08